- Home
- ALDX vs FATE Comparison
ALDX vs FATE Comparison
Compare ALDX & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDX
- FATE
- Stock Information
- Founded
- ALDX 2004
- FATE 2007
- Country
- ALDX United States
- FATE United States
- Employees
- ALDX N/A
- FATE N/A
- Industry
- ALDX Biotechnology: Pharmaceutical Preparations
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALDX Health Care
- FATE Health Care
- Exchange
- ALDX Nasdaq
- FATE Nasdaq
- Market Cap
- ALDX 160.8M
- FATE 177.7M
- IPO Year
- ALDX 2014
- FATE 2013
- Fundamental
- Price
- ALDX $4.76
- FATE $1.14
- Analyst Decision
- ALDX Strong Buy
- FATE Hold
- Analyst Count
- ALDX 2
- FATE 7
- Target Price
- ALDX $9.50
- FATE $3.83
- AVG Volume (30 Days)
- ALDX 1.2M
- FATE 1.9M
- Earning Date
- ALDX 07-31-2025
- FATE 08-12-2025
- Dividend Yield
- ALDX N/A
- FATE N/A
- EPS Growth
- ALDX N/A
- FATE N/A
- EPS
- ALDX N/A
- FATE N/A
- Revenue
- ALDX N/A
- FATE $13,335,000.00
- Revenue This Year
- ALDX N/A
- FATE N/A
- Revenue Next Year
- ALDX N/A
- FATE N/A
- P/E Ratio
- ALDX N/A
- FATE N/A
- Revenue Growth
- ALDX N/A
- FATE 105.85
- 52 Week Low
- ALDX $1.14
- FATE $0.66
- 52 Week High
- ALDX $7.20
- FATE $5.92
- Technical
- Relative Strength Index (RSI)
- ALDX 78.74
- FATE 46.69
- Support Level
- ALDX $4.12
- FATE $1.05
- Resistance Level
- ALDX $4.60
- FATE $1.18
- Average True Range (ATR)
- ALDX 0.29
- FATE 0.08
- MACD
- ALDX 0.08
- FATE -0.00
- Stochastic Oscillator
- ALDX 90.91
- FATE 54.76
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.